Lindsey Vonn is back on her feet after a wicked crash at the Olympics nearly cost her a leg. However, she suffered from ...
Scholar Rock Holding has resubmitted its application for its spinal muscular atrophy treatment to the Food and Drug Administration. The biopharmaceutical company said that it has sent in a new ...
Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress March 31, 2026 8:00 ...
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with ...
Biogen (BIIB) just cleared two important milestones, with FDA approval of a new High Dose Regimen for SPINRAZA in spinal muscular atrophy and positive Phase 2 data for litifilimab in cutaneous lupus ...
Scholar Rock (SRRK) stock jumps as the company resubmits its marketing application for its lead drug, apitegromab, against ...
On March 30, 2026, the FDA approved a high dose regimen for Spinraza (nusinersen) for the treatment of spinal muscular atrophy.
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc ...
Bengaluru: The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza ...
The FDA has approved a higher-dose regimen of Spinraza for spinal muscular atrophy, providing a new treatment option for ...
Zacks.com on MSN
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Shares of Biogen BIIB rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. The new dosing regimen ...
Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results